Enabling Subcutaneous Delivery for Improved Patient Compliance & Healthcare System Efficiencies
Nanoform Biologics’ high-dose subcutaneous delivery platform represents a significant advancement…
Invitation to Nanoform’s Q4 and FY 2024 Report Presentation
Press release Nanoform Finland Plc February 13, 2025 11:00 a.m.…
